Total Revenue Growth1 |
17% to 24% |
Galafold Revenue Growth1 |
10% to 15% |
Pombiliti + Opfolda Growth1 |
65% to 85% |
Gross Margin |
Mid 80% |
Non-GAAP Operating Expenses4 |
$350M to $370M |
GAAP Net Income |
Positive during H2 2025 |
More on Amicus Therapeutics
- Amicus Therapeutics: Cheap Heading Into 2025
- Amicus Therapeutics FY 2024 Earnings Preview
- Amicus Therapeutics expects 2024 revenue slightly above consensus, guides 2025
- Seeking Alpha’s Quant Rating on Amicus Therapeutics
- Historical earnings data for Amicus Therapeutics